Mandate

Vinge acts as counsel to Orkla in connection with the acquisition of Health and Sports Nutrition Group

November 21, 2017 EU, Competition and Regulatory

Vinge acts as counsel to Orkla in connection with the acquisition of Health and Sports Nutrition Group HSNG AB (”HSNG”). The seller is Qliro Group AB (publ).

HSNG is a leading actor within e-commerce of health and sport nutrition in the Nordics and runs its business mainly through the internet stores Gymgrossisten.com and Bodystore.com. In addition, Gymgrossisten has physical franchise stores.

Orkla is a leading supplier of branded consumer goods and concept solutions to the grocery, out-of-home and bakery markets in the Nordics, Baltics and selected markets in Central Europe and India. Orkla is listed on the Oslo Stock Exchange and its head office is in Oslo. In 2016, the Group had a turnover of approximately NOK 38 billion, and 18,000 employees at year end.

The transaction is subject to the approval of the relevant competition authorities.

Vinge’s team consists, among others, of responsible partner Peter Sundgren as well as counsel Joacim Rydergård and associates Christina Odengran, Christoffer Nordin, Emelie Håkansson, Mika Jordan, Sara Strandberg, Filip Markhed and Ilze Lukins. Partner Johan Karlsson as well as, among others, associates Trine Osen Bergqvist and Xandra Ståhlberg are advising on competition law issues.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026